[Intra-arterial chemotherapy with gemcitabine (GEM) for unresectable pancreatic cancer]

Gan To Kagaku Ryoho. 2002 Nov;29(12):2065-9.
[Article in Japanese]

Abstract

Purpose: Most patients with pancreatic cancer are unresectable because of local invasion and liver metastasis at the time of diagnosis. To date, no treatment has had a significant impact on this disease. To deliver a high concentration of drug to the cancer, intra-arterial chemotherapy with GEM was performed in two patients with unresectable advanced cancer.

Patients and methods: One patient, a 70-year-old man with liver metastasis, was treated with arterial infusion of GEM 1,000 mg/body. Another patient, a 55-year-old woman with local invasion and distant metastatic lymphadenopathy, was given intra-arterial infusion of GEM 400 mg and intra-venous infusion of GEM 1,000 mg/body. The patients were given GEM weekly for 3 weeks followed by a week of rest.

Results: In the first patient, the pain went away and CEA was decreased for 6 months. After that, the patient died due to intra-abdominal dissemination within 4 months. In the other patient, the pain went away. Tumor markers, such as CEA and CA19-9, were normalized and primary pancreatic cancer was reduced locally. The patient currently has a metastatic liver tumor, but she has had a significant improvement in performance status.

Conclusion: Intra-arterial chemotherapy with GEM may be tolerated in patients with unresectable pancreatic cancer.

Publication types

  • Case Reports
  • English Abstract

MeSH terms

  • Aged
  • Antimetabolites, Antineoplastic / administration & dosage*
  • Deoxycytidine / administration & dosage*
  • Deoxycytidine / analogs & derivatives*
  • Female
  • Gemcitabine
  • Humans
  • Infusions, Intra-Arterial
  • Infusions, Intravenous
  • Liver Neoplasms / secondary
  • Male
  • Middle Aged
  • Pancreatic Neoplasms / drug therapy*

Substances

  • Antimetabolites, Antineoplastic
  • Deoxycytidine
  • Gemcitabine